Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 01, 2025 08:54 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : Yves Jacob nommé responsable R&D France de Sanofi à compter du 1er septembre

Yves Jacob nommé responsable R&D France de Sanofi à compter du 1er septembre Gentilly (France), le 1er septembre 2025 – Sanofi annonce la nomination d’Yves Jacob en tant que Responsable R&D...
September 01, 2025 08:47 ET | Source: King Faisal Specialist Hospital & Research Centre

KFSHRC to Participate as Strategic Partner in C3 Davos of Healthcare New York Summit

NEW YORK, Sept. 01, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is participating as a Strategic Partner in the C3 Davos of Healthcare New York Summit,...
September 01, 2025 04:00 ET | Source: Oculis Holding AG

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01...
September 01, 2025 03:05 ET | Source: Boehringer Ingelheim Limited

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1...
August 31, 2025 15:51 ET | Source: CrazyBulk

Anavar For Women And Men: CrazyBulk Launch Anavar Legal Steroid Alternative For Female Read Dosage, Side Effects, (Before and After Cycle results)

New York, Aug. 31, 2025 (GLOBE NEWSWIRE) -- August 31, 2025 | New York CrazyBulk proudly announces the release of Anavar (Anvarol), its legal and safe alternative to the anabolic steroid Anavar....
August 31, 2025 10:23 ET | Source: Tourmaline Bio, Inc.

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
August 31, 2025 10:15 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb Participants had the Nonobstructive Form of HCM for...
August 30, 2025 08:30 ET | Source: Amarin Corporation plc

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -- DUBLIN and...
August 29, 2025 17:00 ET | Source: Biogen Inc.

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial...
August 29, 2025 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...